AlloVir, Inc.
ALVR · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.01 | 0.02 | 0.12 | -0.81 |
| FCF Yield | -141.24% | -177.84% | -36.50% | -13.24% |
| EV / EBITDA | 1.08 | -0.04 | -1.91 | -3.72 |
| Quality | ||||
| ROIC | -57.76% | -104.62% | -65.77% | -65.22% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 1.15 | 0.65 | 0.84 | 0.62 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | -100.00% |
| Free Cash Flow Growth | 45.60% | 12.33% | -33.48% | -74.20% |
| Safety | ||||
| Net Debt / EBITDA | 1.81 | 0.33 | 0.42 | 1.01 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | -16.34 | -22.34 |
| Cash Conversion Cycle | 0.00 | -6,200.41 | -449.81 | -2,748.45 |